Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Transcatheter Treatment of Tricuspid Valve Regurgitation

NCT06093828 · tracked via the Priya Life Science Italy tracker
Sponsor
TriFlo Cardiovascular, Inc
Phase
Not applicable
Started
2024-10
Last updated
2023-10-23

Condition(s) studied

Symptomatic Severe Tricuspid Regurgitation

Investigational drug(s) / intervention(s)

TriFlo Tricuspid Flow Optimizer

TriFlo Tricuspid Flow Optimizer: An introducer sheath is inserted into the femoral vein over a stiff guidewire; the sheath extends into the common iliac vein and inferior vena cava and in the right atrium. The TFO device is oriented coaxiality to the tricuspid. Once released, the delivery catheter and the steerable catheter are removed the access site closure performed by a cardiovascular or vascular surgeon or with pre-implanted percutaneous sutures per site preference.

Study summary

Tricuspid Regurgitation induces an asymmetric enlargement of the tricuspid valve (TV) annulus causing a reduction of leaflets coaptation. Annular dilation continues even after surgical treatment. The progressive nature of TR, inadequate surgical treatment, and high-risk patient population make TR an ideal target for transcatheter therapy. The TriFlo TFO System introduces a new concept for the treatment of tricuspid regurgitation. Its commissural anchoring is designed to respect TV leaflet integrity, mobility, and maintain RV contractility.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 years or older 2. Symptomatic severe tricuspid regurgitation 3+ on a scale of 0+ to 5+, according to semi-quantitative echocardiographic color flow doppler evaluation 3. Tricuspid valve (TV) morphology which fulfills anatomic criteria of eligibility for the device according to Imaging Core Lab assessment 4. Signed (by subject or legal representative) and dated approved subject informed consent form prior to any study related procedure 5. Available and able to return to the study site for post-procedural follow-up examination Exclusion Criteria: CARDIOVASCULAR EXCLUSION CRITERIA 1. Requirement for an interventional percutaneous procedure or cardiac surgical procedure \<30 days before or after index procedure 2. Prior tricuspid repair or replacement, implantation of an artificial heart valve. 3. Active endocarditis or history of endocarditis within the previous 12 months. 4. Left Ventricular Ejection Fraction \<30% 5. Severe aortic and mitral stenosis and/or regurgitation 6. Severe tricuspid valve stenosis 7. Severe right ventricular failure 8. Systolic Pulmonary Artery pressure \>70 mmHg 9. Echocardiographic evidence of intracardiac mass, thrombus, tumor, myxoma or vegetation 10. Femoral vein, inferior vena cava or evidence of intracardiac thrombus not adequately treated 11. Presence of an occluded or thrombosed inferior vena cava (IVC) filter that would interfere with the delivery catheter, or ipsilateral deep vein thrombosis is present. 12. Trans-tricuspid Pacemaker leads implanted within 90 days before the index procedure. EXCLUSION DUE TO COMORBIDITIES 13. Cerebrovascular event within the previous 6 months. 14. Myocardial infarction within 30 days prior to enrollment. 15. Bleeding disorders or hypercoagulable state, thrombocytopenia (platelet count \<100,000/mm3), thrombocytosis (\>750,000/mm3) or patient who refuses blood transfusions. 16. Acute anemia Hb\<8 g/dl not adequately treated or white blood cell count\<1000. 17. Severe renal failure requiring chronic dialysis or eGFR\<25. 18. Severe Liver disfunction - class C cirrhosis. 19. Severe CLD with oxygen dependent COPD. 20. Coronary artery disease requiring revascularization EXCLUSION DUE TO CONTRAINDICATIONS 21. Unable to undergo transesophageal echocardiogram (TEE) and cardiac computed tomography (CT) or screening TEE is unsuccessful. 22. Contraindication, hypersensitivity or known allergy to device's components (nickel or titanium), aspirin, anti-coagulation and antiplatelet therapy or contrast media that cannot be adequately pre-medicated. 23. Known intolerance to anti-coagulation treatments. GENERAL EXCLUSION CRITERIA 24. Female patient pregnant (urine HCG test result positive) or lactating. 25. Known alcohol or drug abuser. 26. Currently participating in the study of an investigational drug or device. 27. Neoplasia with Life expectancy \< 12 months

Primary outcome measure(s)

  • Acute safety, defined as freedom from device- or procedure-related Major Adverse Events (MAE) — 30 days
    a composite of death, Q-wave myocardial infarction, cardiac tamponade, cardiac surgery for failed TFO implantation, bleeding).

Trial sites (4)

FacilityCityRegionStatus
Pineta Grande Hospital Castel Volturno Caserta
IRCCS Humanitas Research Hospital Rozzano Milano
IRCCS Policlinico San Donato San Donato Milanese Milano
Policlinico Campus Biomedico Roma Italy
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06093828 on ClinicalTrials.gov ↗ ← All trials in Italy